

BioBusiness Asia 2009

Company Name	Adlyfe Inc.		
Presenter	Roxanne Duan, Ph.D.	Title	President
Address	9430 Key West Ave., Rockville, MD 20850		
Website	www.adlyfe.com		
No. of employee	9	Year of foundation	5
Company Categories	<input type="checkbox"/> Novel Therapeutics <input type="checkbox"/> Genomics <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> R&D Service <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other <u> Diagnostics </u>		
Paid-in Capital	11 million USD		
Company Stage	<input type="checkbox"/> Seed <input type="checkbox"/> Start up * <input type="checkbox"/> Expansion <input type="checkbox"/> Mezzanine		
Company Overview	<p>Adlyfe is an expansion stage biotech company located in Rockville, Maryland, USA, focusing on early diagnosis of fatal protein misfolded diseases. Adlyfe's novel Pronucleon™ ligand platform enables early diagnosis and early therapeutic intervention for Alzheimer's disease and over 40 other misfolded amyloid protein diseases.</p>		
Company History	<p>Established early in 2003, Adlyfe is dedicated to early detection and treatment of fatal protein misfolded diseases. Adlyfe's novel Pronucleon™ ligand platform enables early diagnosis and early therapeutic intervention for over 40 misfolded amyloid protein diseases. We have demonstrated experience in clinical detection of protein misfolded diseases with early focus on Alzheimer's disease. We are developing both in vitro diagnostic and in vivo imaging agents that will enable effective clinical diagnosis in patients presenting with the first symptoms of protein misfolding diseases. The platform also has potential in the development of new effective anti-amyloid therapeutics.</p> <p>Adlyfe licensed its platform technology from Arete in 2004 and established methods for early detection of prion (TSE) disease. In 2006, Adlyfe raised its A round funding to re-focus on Alzheimer's disease diagnosis. In 2008, Adlyfe demonstrated detection methods for Amyloid beta oligomers, toxic species to neurons. Adlyfe has more than a dozen patents filed, with a broad claim patent issued in 2007. Adlyfe established collaboration with Wyeth in 2009. Currently, Adlyfe is raising its B round funding.</p>		
Main Products/ Service & Niche of Products/ Service	<p>Diagnostic products including in vitro clinical diagnostic kits and diagnostic imaging agents for early detection of Alzheimer's disease and other protein misfolding diseases</p>		
Market Potentials			
Company Core Competence or Competitive Advantage			
Partnering Objectives			